A 2015 update on predictive molecular pathology and its role in targeted cancer therapy: a review focussing on clinical relevance

…, C Denkert, S Darb-Esfahani, D Lenze… - Cancer gene …, 2015 - nature.com
In April 2013 our group published a review on predictive molecular pathology in this journal.
Although only 2 years have passed many new facts and stimulating developments have …

[HTML][HTML] A biologic definition of Burkitt's lymphoma from transcriptional and genomic profiling

…, D Hasenclever, M Kühn, D Lenze… - … England Journal of …, 2006 - Mass Medical Soc
Background The distinction between Burkitt's lymphoma and diffuse large-B-cell lymphoma
is unclear. We used transcriptional and genomic profiling to define Burkitt's lymphoma more …

Senescence-associated reprogramming promotes cancer stemness

…, Z Zhao, Y Yu, JR Dörr, L Dimitrova, D Lenze… - Nature, 2018 - nature.com
Cellular senescence is a stress-responsive cell-cycle arrest program that terminates the
further expansion of (pre-) malignant cells,. Key signalling components of the senescence …

Synthetic lethal metabolic targeting of cellular senescence in cancer therapy

…, G Beuster, C Zasada, JHM Däbritz, J Lisec, D Lenze… - Nature, 2013 - nature.com
Activated oncogenes and anticancer chemotherapy induce cellular senescence, a terminal
growth arrest of viable cells characterized by S-phase entry-blocking histone 3 lysine 9 …

Derepression of an endogenous long terminal repeat activates the CSF1R proto-oncogene in human lymphoma

…, K Walter, S Kreher, R Kumar, M Hummel, D Lenze… - Nature medicine, 2010 - nature.com
Mammalian genomes contain many repetitive elements, including long terminal repeats
(LTRs), which have long been suspected to have a role in tumorigenesis. Here we present …

Reprogramming of miRNA networks in cancer and leukemia

…, TJ Kipps, K Huebner, F Pichiorri, D Lenze… - Genome …, 2010 - genome.cshlp.org
We studied miRNA profiles in 4419 human samples (3312 neoplastic, 1107 nonmalignant),
corresponding to 50 normal tissues and 51 cancer types. The complexity of our database …

PTEN loss defines a PI3K/AKT pathway-dependent germinal center subtype of diffuse large B-cell lymphoma

M Pfeifer, M Grau, D Lenze… - Proceedings of the …, 2013 - National Acad Sciences
Diffuse large B-cell lymphoma (DLBCL) represents a heterogeneous diagnostic category
with distinct molecular subtypes that can be defined by gene expression profiling. However …

Clinical Impact of the Cell-of-Origin Classification and the MYC/BCL2 Dual Expresser Status in Diffuse Large B-Cell Lymphoma Treated Within Prospective Clinical …

…, M Hummel, H Stein, D Lenze… - Journal of clinical …, 2017 - ascopubs.org
Purpose To explore the prognostic impact and interdependence of the cell-of-origin (COO)
classification, dual expression (DE) of MYC and BCL2 proteins, and MYC, BCL2, and BCL6 …

Modeling the regional impact of natural disaster and recovery: A general framework and an application to Hurricane Andrew

CT West, DG Lenze - International regional science review, 1994 - journals.sagepub.com
Two common features of natural disasters are intense regional impact and the call
immediately after the event to estimate the economic impact of recovery and reconstruction …

Immunoblastic morphology but not the immunohistochemical GCB/nonGCB classifier predicts outcome in diffuse large B-cell lymphoma in the RICOVER-60 trial of the …

…, C Thorns, AC Feller, D Lenze… - Blood, The Journal …, 2010 - ashpublications.org
The survival of diffuse large B-cell lymphoma patients varies considerably, reflecting the
molecular diversity of tumors. In view of the controversy whether cytologic features …